AU2173400A - Method for administering agents to the central nervous system - Google Patents

Method for administering agents to the central nervous system

Info

Publication number
AU2173400A
AU2173400A AU21734/00A AU2173400A AU2173400A AU 2173400 A AU2173400 A AU 2173400A AU 21734/00 A AU21734/00 A AU 21734/00A AU 2173400 A AU2173400 A AU 2173400A AU 2173400 A AU2173400 A AU 2173400A
Authority
AU
Australia
Prior art keywords
nervous system
central nervous
administering agents
agents
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21734/00A
Other languages
English (en)
Inventor
William H. Ii Frey
Robert Gary Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2173400A publication Critical patent/AU2173400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU21734/00A 1998-12-09 1999-12-09 Method for administering agents to the central nervous system Abandoned AU2173400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20853998A 1998-12-09 1998-12-09
US09208539 1998-12-09
PCT/US1999/029335 WO2000033814A2 (en) 1998-12-09 1999-12-09 Method for administering agents to the central nervous system

Publications (1)

Publication Number Publication Date
AU2173400A true AU2173400A (en) 2000-06-26

Family

ID=22774961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21734/00A Abandoned AU2173400A (en) 1998-12-09 1999-12-09 Method for administering agents to the central nervous system

Country Status (6)

Country Link
EP (1) EP1135105B1 (enExample)
JP (1) JP2002531490A (enExample)
AT (1) ATE289800T1 (enExample)
AU (1) AU2173400A (enExample)
DE (1) DE69923998T2 (enExample)
WO (1) WO2000033814A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1602378A1 (en) * 1999-12-09 2005-12-07 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US20100160293A1 (en) * 2005-02-17 2010-06-24 Kakuji Tojo Solid Ophthalmic Drug for External Use
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
KR101760139B1 (ko) 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
RU2692251C2 (ru) 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
PT3220891T (pt) 2014-11-21 2019-10-31 Biohaven Pharm Holding Co Ltd Formulação sublingual de riluzol
PL3865563T3 (pl) 2014-11-25 2024-01-29 Corning Incorporated Materiały i sposoby do przedłużania pożywki do hodowli komórkowej
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
WO2017017543A1 (en) * 2015-07-30 2017-02-02 U R Anoop Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
CN115814055A (zh) 2016-04-12 2023-03-21 三叉神经股份公司 含镁催产素制剂和应用方法
WO2017181113A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
NZ751690A (en) * 2016-09-07 2022-02-25 Glia Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002271A1 (en) * 1984-10-19 1986-04-24 Chiron Corporation Promotion of wound healing with human epidermal growth factor prepared from recombinant dna
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2735293A1 (en) * 1995-01-17 1996-07-18 Menuco Corp. Nadh and nadph therapeutic agents for dermal administration
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale

Also Published As

Publication number Publication date
DE69923998D1 (de) 2005-04-07
EP1135105B1 (en) 2005-03-02
ATE289800T1 (de) 2005-03-15
EP1135105A2 (en) 2001-09-26
WO2000033814A2 (en) 2000-06-15
JP2002531490A (ja) 2002-09-24
DE69923998T2 (de) 2006-04-27
WO2000033814A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
AU2173400A (en) Method for administering agents to the central nervous system
AU2049500A (en) Administration of neurotrophic agents to the central nervous system
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
AU3402295A (en) Methods and means for drug administration
AU2339792A (en) Treatment of respiratory disorders by nerve stimulation
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
PL398445A1 (pl) Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
EP1014881A4 (en) TREATMENT OF NEURODEGENERATIVE CONDITIONS BY INFUSION OF NERVOUS GROWTH FACTORS IN THE BRAIN
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
PL316313A1 (en) Naphtyloamides as agents acting on a central nerve system
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
MY135838A (en) Methods for the treatment of mental disorders
EP1085862A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASES
MXPA02012626A (es) Bis-arilsufonas.
GB9212308D0 (en) Therapeutic compositions
WO2003066071A8 (en) Formulations comprising psychotropic drugs and selenium
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
MXPA02005667A (es) Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
MXPA03001160A (es) Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
IL143382A0 (en) Human adult astrocytes, their preparation and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase